Navigation Links
Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
Date:4/9/2008

ion Center

Preclinical data providing new details on SNS-314's anti-tumor activity will be presented Wednesday, April 16, 2008. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors.

SNS-314 Poster Presentation

Wednesday, April 16, 2008

-- SNS-314, a potent inhibitor of Aurora kinases, has preclinical

anti-activity and induces apoptosis

Session: Heat Shock Protein Inhibitors, Aurora Kinase and other Mitotic

Inhibitors

Abstract #5648

8:00 a.m. - 12:00 p.m. Exhibit Hall B-F, San Diego Convention Center

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
2. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
3. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
4. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
7. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
8. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
9. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
10. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
11. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... -- Eli Lilly and Company (NYSE: LLY ) ... comprehensive overview of the company,s corporate responsibility efforts. ... approach to corporate responsibility by increasingly leveraging its ... have greater, more sustainable impact. The ... thorough look at the company,s progress on numerous ...
(Date:5/4/2015)... NASHVILLE, Tenn. , May 4, 2015  Verus ... after its acquisition of CPAP Care Club in 2012.  ... CPAP business within the durable medical equipment (DME) industry ... apnea patients for their CPAP supply needs and processes ... we bought this company three years ago, the systems ...
(Date:5/4/2015)... , May 4, 2015 CytoSorbents ... company commercializing its CytoSorb® extracorporeal cytokine adsorber to ... countries worldwide, will report Q1 2015 financial results ... 2015.  CytoSorbents, management will host ... will recount both operational and financial progress during ...
Breaking Medicine Technology:Lilly Releases Corporate Responsibility, Global Health Reports 2Lilly Releases Corporate Responsibility, Global Health Reports 3Lilly Releases Corporate Responsibility, Global Health Reports 4Verus Healthcare Celebrates 1,000% Growth on Third Anniversary 2CytoSorbents to Report Q1 2015 Operating and Financial Results 2CytoSorbents to Report Q1 2015 Operating and Financial Results 3
... for maintaining a healthy immune systemPURCHASE, N.Y., Jan. 6 ... Cancer (60(5), 643-651) by researchers at Kansai Medical ... Hexose Correlated Compound) enhances immune function by increasing the ... part of the immune system responsible for presenting foreign ...
... 6 Pacira Pharmaceuticals, Inc., an,acute care specialty ... in two pivotal Phase III SIMPLE trials to ... administration of EXPAREL(TM),(DepoBupivacaine) for prolonged postoperative analgesia. , ... in hemorrhoidectomy and in total knee,arthroplasty (TKA) are ...
Cached Medicine Technology:Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 2Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 3Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3
(Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – ... innovative lymphoma research and serving the lymphoma community through ... patient services – is set to host its annual ... West Orange, NJ on June 1, 2015. Since 2010, ... programs through LRF. , This year, the Lymphoma Research ...
(Date:5/4/2015)... The opportunity for children to dream of ... motivating forces behind The Fairy Godmother Next Door, a new ... L. Stark. , The inspiration for the enchanting story of ... from Stark’s desire to be a fairy godmother. , “My ... to my neighbors’ children since they were born. We discuss ...
(Date:5/4/2015)... 2015 In May of 2010, after two ... life. In the wake of this tragedy, Ty’s parents Kirk ... that exposes the grim reality of bullying and its devastating ... Kirk and Laura to share their story and offer education ... to another family — a mission that took the Smalley ...
(Date:5/4/2015)... May 04, 2015 The U.S. healthcare ... boomers join the ranks of senior citizens (1) and ... an already over-burdened healthcare system. Additionally, as older healthcare ... replace them. Per the U.S. Census Bureau, the number ... increase 75% by 2050 while those 25 to 54 ...
(Date:5/4/2015)... Ticket Down is a reputable source for ... . While the World Cup is the most known ... years, the International Champions Cup is one of the biggest ... attendance record for soccer in the United States set when ... the University of Michigan. This year, the defending champion Manchester ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4
... to Demonstrate Single-Agent Activity, - 38% Response Rate, 43% Disease Control ... Refractory Hodgkin Lymphoma ... in 110mg Cohort, ... Including an 18% Response Rate in Evaluable Diffuse Large B- cell ...
... that has saved more than 100,000 lives, now is saving ... disease progression with long term use in adults with chronic ... continues to show how much Gleevec has completely changed the ... Druker, M.D., director of the OHSU Cancer Institute. , ...
... ATLANTA, GA, December 8, 2007 -- Results from two ... with bortezomib provide preliminary anti-tumor activity in patients with ... study showed that 10 of 21 (48 percent) evaluable ... ZOLINZA and bortezomib combination treatment. Data from a ...
... 8, 2007 There is a clear link between GABA ... that inhibits neurons in the brain and ... the American College of Neuropsychopharmacology (ACNP) annual meeting. Researchers ... a finding which could potentially help curb the pleasurable ...
... Boca Raton, FL, December 8, 2007 Bipolar disorder, ... the circadian system the bodys internal clock ... irregularities in the circadian system that can trigger key ... today at the American College of Neuropsychopharmacology (ACNP) annual ...
... Dec. 7 On the heels of today,s,Human ... immigrant,detainees, AIDS Healthcare Foundation (AHF) today criticized the ... disregard for the,health and well-being of people living ... Indifference: HIV/AIDS Services for Immigrants,Detained by the U.S.," ...
Cached Medicine News:Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 2Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 3Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 4Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 5Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 6Health News:Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting 7Health News:Gleevec, the targeted cancer pill, delivers more good news to patients 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 3Health News:Study suggests nicotine addiction might be controlled by influencing brain mechanisms 2Health News:Studies find stable sleep patterns and regular routines may improve outcomes in bipolar disorder 2Health News:Studies find stable sleep patterns and regular routines may improve outcomes in bipolar disorder 3Health News:Denial of Care for HIV+ Detainees 'Unacceptable,' Says AHF 2
... Graham-Field has been developing ... than 58 years. Our medical-surgical ... reputation for innovation, quality and ... brands include the Labtron® line ...
... Vibrating Mesh Technology to efficiently deliver ... Asthma, COPD or other respiratory conditions. ... and handy carrying case that is ... Powerful delivery comparable to table-top compressor ...
... deliver particulate humidity in the 3 to ... patients. For your convenience, Thera-Mist® nebulizers may ... sterile water., ,The P30000N, for normal ... with a total flow range of 68-24 ...
... as well as humidification, try Flo-Mist™., ... volume, continuous medication nebulizer (CMN), engineered to ... 200 ml reservoir and jet flow design ... nebulized medication delivery at 25 ml/hr. Particles ...
Medicine Products: